⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Official Title: Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)

Study ID: NCT05147272

Study Description

Brief Summary: The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

Detailed Description: Phase 1, multi-center, open-label, dose-escalation study to: * Evaluate the safety profile and MTD of RP-6306 with gemcitabine to establish the RP2D and schedule * Characterize the PK and pharmacodynamics of RP-6306 with gemcitabine * Assess preliminary anti-tumor activity associated with RP-6306 with gemcitabine

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Participating site # 1018, Phoenix, Arizona, United States

Participating site # 1019, Los Angeles, California, United States

Participating site # 1017, Jacksonville, Florida, United States

Participating Site #1022, Tampa, Florida, United States

Participating Site # 1023, Grand Rapids, Michigan, United States

Participating site # 1016, Rochester, Minnesota, United States

Participating Site # 1008, New York, New York, United States

Participating Site # 1004, New York, New York, United States

Participating Site # 1010, Philadelphia, Pennsylvania, United States

Participating site # 2001, Toronto, Ontario, Canada

Participating site # 3003, London, , United Kingdom

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: